| An update on neurofibromatosis type 1-associated gliomas M Lobbous, JD Bernstock, E Coffee, GK Friedman, LK Metrock, ... Cancers 12 (1), 114, 2020 | 91 | 2020 |
| Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine … EM Stringer-Reasor, BJ O'Brien, A Topletz-Erickson, JB White, M Lobbous, ... Journal of Clinical Oncology 39 (15_suppl), 1044-1044, 2021 | 28 | 2021 |
| Routine use of low-dose glucarpidase following high-dose methotrexate in adult patients with CNS lymphoma: an open-label, multi-center phase I study LR Schaff, M Lobbous, D Carlow, R Schofield, IT Gavrilovic, AM Miller, ... BMC cancer 22, 1-10, 2022 | 11 | 2022 |
| Racial and socioeconomic disparities in glioblastoma outcomes: A single‐center, retrospective cohort study D Estevez‐Ordonez, M Abdelrashid, E Coffee, NMB Laskay, TJ Atchley, ... Cancer 129 (19), 3010-3022, 2023 | 10 | 2023 |
| Neurofibromatosis type 1 (NF1): Management and prognosis BR Korf UpToDate. com. Waltham, MA: Wolters Kluwer, 4, 2015 | 9 | 2015 |
| Cauda equina syndrome in an ovarian malignant‐mixed müllerian tumor with leptomeningeal spread JD Bernstock, S Ostby, B Fox, H Sotoudeh, A Janssen, YJ Kang, J Chen, ... Clinical Case Reports 7 (12), 2341-2345, 2019 | 6 | 2019 |
| Phase 1 trial of drug resistant immunotherapy: A first-in-class combination of MGMT-modified γδ t cells and temozolomide chemotherapy in newly diagnosed glioblastoma. LB Nabors, LS Lamb, MJ Beelen, T Pillay, M ter Haak, S Youngblood, ... Journal of Clinical Oncology 39 (15_suppl), 2057-2057, 2021 | 5 | 2021 |
| Treatment of pediatric high‐grade central nervous system tumors with high‐dose methotrexate in combination with multiagent chemotherapy: a single‐institution experience JD Bernstock, E Alva, JL Cohen, M Lobbous, G Chagoya, GA Elsayed, ... Pediatric Blood & Cancer 67 (3), e28119, 2020 | 5 | 2020 |
| Child neurology: childhood basilar artery occlusion and stroke M Lobbous, S Williams, S Rashid Neurology 89 (7), e68-e70, 2017 | 5 | 2017 |
| CTIM-13. Phase I clinical trial of oncolytic HSV-1 M032, a second-generation virus armed to expressed IL-12, for the treatment of adult patients with recurrent or progressive … D Estevez-Ordonez, J Stein, P Maleknia, C Gallegos, T Atchley, N Laskay, ... Neuro-Oncology 25 (Suppl 5), v64, 2023 | 4 | 2023 |
| The role of targeted therapy and immune therapy in the management of non-small cell lung cancer brain metastases C Billena, M Lobbous, CA Cordova, D Peereboom, A Torres-Trejo, ... Frontiers in Oncology 13, 1110440, 2023 | 4 | 2023 |
| Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in HER2+ breast cancer: TBCRC049 phase 2 study results. BJ O'Brien, RK Murthy, DA Berry, A Singareeka Raghavendra, ... Journal of Clinical Oncology 42 (16_suppl), 2018-2018, 2024 | 3 | 2024 |
| INB-200 phase I study of gene modified autologous gamma-delta (γδ) T cells in patients with newly diagnosed glioblastoma multiforme (GBM) receiving maintenance temozolomide (TMZ). M Lobbous, T Goswami, LS Lamb, K Rochlin, T Pillay, S Youngblood, ... Journal of Clinical Oncology 41 (16_suppl), 2007-2007, 2023 | 3 | 2023 |
| Undesired impact of iron supplement on MRI assessment of post-treatment glioblastoma D Park, M Lobbous, LB Nabors, JM Markert, J Kim CNS oncology 11 (4), CNS92, 2022 | 3 | 2022 |
| Prevalence of asymptomatic glioma and implications for survival PP Warren, M Lobbous, NC Peeri, ZJ Thompson, RC Thompson, JJ Olson, ... MedRxiv, 2020.04. 27.20080564, 2020 | 3 | 2020 |
| Therapeutic development in neurofibromatosis M Lobbous, BR Korf Neurofibromatosis Curr. Trends Futur. Dir, 2019 | 3 | 2019 |
| LTBK-09. Results of BMX-HGG study: A multi-institutional, randomized phase 2 clinical trial of concurrent chemoradiation with or without BMX-001 in patients with newly … K Peters, A Cohen, N Butowski, J Villano, J Mendez, P Giglio, ... Neuro-oncology 25 (Supplement_5), v311-v311, 2023 | 2 | 2023 |
| Pain among older adults with gastrointestinal malignancies-results from the cancer and aging resilience evaluation (CARE) Registry M Al-Obaidi, S Kosmicki, C Harmon, M Lobbous, D Outlaw, M Khushman, ... Supportive Care in Cancer 30 (12), 9793-9801, 2022 | 2 | 2022 |
| Phase I study of drug-resistant immunotherapy (DRI) with gene-modified autologous γδ T cells in patients with newly diagnosed glioblastoma multiforme (GBM) receiving … LB Nabors, M Lobbous, LS Lamb, K Rochlin, T Pillay, S Youngblood, ... Journal of Clinical Oncology 40 (16_suppl), 2044-2044, 2022 | 2 | 2022 |
| An evaluation of selumetinib for the treatment of neurofibromatosis type 1-associated symptomatic, inoperable plexiform neurofibromas LK Metrock, M Lobbous, B Korf Expert Review of Precision Medicine and Drug Development 6 (4), 239-246, 2021 | 2 | 2021 |
